News from NORD
LOS ANGELES – “Durable and persistent” benefit seen in open-label trial of cerliponase alfa in neuronal ceroid lipofuscinosis type 2 disease.
Daily News Podcast
And bum kidneys shouldn’t stop dabigatran reversal.
LOS ANGELES – Members of the AAN Neurology Drug Pricing Task Force spoke about the issues that arise in getting patients access to high-cost drugs...
The bill passed despite opposition from a broad coalition of physician and patient groups.
Hizentra is the first FDA-approved subcutaneously administered human immunoglobulin maintenance therapy for CIDP.
NAPLES, FL—Although patients with symptomatic neurosarcoidosis account for approximately 5% to 15% of people with systemic sarcoidosis, making it...
SAN DIEGO—Developments in strategies based on CRISPR and antisense oligonucleotides (ASOs) have raised the prospect that these therapies targeting...
From the Journals
Results cast doubt on the validity of the FDA’s advisory warning in 2006.